glp-1 market news november 2025 Receptor Agonist Growth Analysis ISPOR 2025: Exploring reasons for

& Harris, M

Patients prone to heart disease might fare best on medication that includes a GLP-1 component

It doesn't mean weight loss is easy

Decreased immune activity in the tumor microenvironment could contribute to poor prognosis and an inability to mitigate tumor growth, potentially due to immunosuppression by cancer cells or other immunosuppressive populations in the tumor microenvironment ( Our study is subject to several limitations

Pollak, M

Summary: GLP-1 medications slow gut motility and gastric emptying, leading to harder stools and constipation, which can be managed through increased dietary fibre, adequate hydration, regular physical activity, and appropriate laxative use when necessary